Clinical Trial Site

Tucson, Arizona 85741

2 studies enrolling now · 9 studies all time

What they study most

Advanced Breast Cancer, Amyloidosis, Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma, Hearing Loss, Sensorineural, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Iron Deficiency Anemia, Leukocyte Chemotactic Factor 2 Amyloidosis, Metastatic Breast Cancer

Studies at this site

• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Recruiting now
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) — Completed
• FX-322 in Adults With Acquired Sensorineural Hearing Loss — Completed
• Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery — Stopped early
• A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia — Completed
• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia — Completed
• A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease — Stopped early